NGL Fine-Chem liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
6.96×————
1.84×1.84×1.98×2.46×2.79×
1.37×1.37×1.55×1.96×2.33×
42.042.060.254.047.3
126126116126104
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NGLFINE₹2,612.80

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,614 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————6.96
Current Ratio2.792.461.981.841.84
Quick Ratio2.331.961.551.371.37
Cash, Equiv & ST Investments47.354.060.242.042.0
Working Capital104.4126.1116.4126.4126.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.